Survival Benefit of Crossover Administration of Regorafenib and Trifluridine/Tipiracil Hydrochloride for Patients With Metastatic Colorectal Cancer: Exploratory Analysis of a Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study (REGOTAS)

Background: The survival benefits of regorafenib (REG) and trifluridine/tipiracil hydrochloride (TFTD) have been demonstrated in chemorefractory patients with metastatic colorectal cancer (mCRC). However, the effects of crossover administration of REG and TFTD on patient survival remain unclear. The...

Descripción completa

Detalles Bibliográficos
Autores principales: Chida, Keigo, Kotani, Daisuke, Moriwaki, Toshikazu, Fukuoka, Shota, Masuishi, Toshiki, Takashima, Atsuo, Kumekawa, Yosuke, Kajiwara, Takeshi, Yamazaki, Kentaro, Komoda, Masato, Makiyama, Akitaka, Denda, Tadamichi, Hatachi, Yukimasa, Suto, Takeshi, Sugimoto, Naotoshi, Enomoto, Masanobu, Ishikawa, Toshiaki, Kashiwada, Tomomi, Ando, Koji, Yuki, Satoshi, Okita, Yoshihiro, Kusaba, Hitoshi, Sakai, Daisuke, Okamoto, Koichi, Tamura, Takao, Yamashita, Kimihiro, Gosho, Masahiko, Shimada, Yasuhiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7982575/
https://www.ncbi.nlm.nih.gov/pubmed/33763345
http://dx.doi.org/10.3389/fonc.2021.576036

Ejemplares similares

Ejemplares similares